Company Reports Q1 Revenue of $27.86M, Below Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy OM?
Reports Q1 revenue $27.86M, consensus $28.9M. "We delivered a solid first quarter and continued to make meaningful progress on our path to profitability, driven by disciplined execution and another quarter of record gross margin performance," said Leslie Trigg, Chair and Chief Executive Officer. "With utilization strong and service margins expanding, we remain focused on driving broader adoption of Tablo across care settings and confident in our full-year outlook."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OM
Wall Street analysts forecast OM stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.680
Low
7.00
Averages
11.75
High
17.00
Current: 4.680
Low
7.00
Averages
11.75
High
17.00
About OM
Outset Medical, Inc. is a medical technology company. It offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. It designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. Tablo comprises various components, including Tablo Console, Tablo Cartridge, and Tablo Data Ecosystem. The Tablo Console is a proprietary, compact, and mobile machine consisting of an integrated water purification, on-demand dialysate production system and simple-to-use touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Outset Medical (OM) Q1 2026 Earnings Transcript
See More
Halper Sadeh LLC Investigates Outset Medical Executives' Responsibilities
- Shareholder Rights Protection: Halper Sadeh LLC is investigating whether executives of Outset Medical, Inc. breached their fiduciary duties, potentially allowing shareholders to seek corporate governance reforms and fund recovery, thereby enhancing company transparency and accountability.
- Legal Fee Arrangement: The law firm commits to handling the case on a no upfront cost basis, meaning shareholders can pursue their legal rights without incurring additional financial burdens, thus lowering the barriers to participation.
- Importance of Shareholder Involvement: Shareholder participation is viewed as crucial for improving company policies and oversight mechanisms, which can drive the company towards more transparent and effective management, ultimately enhancing overall shareholder value.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide affected by securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for victims, demonstrating its strength in protecting investor rights.
See More
Outset Medical Q4 Results Show Strong Analyst Support
- Performance Overview: Outset Medical reported Q4 revenue of $28.90 million, a 2% year-over-year decline, while total revenue for 2025 rose 5% to $119.50 million, indicating efforts in stabilizing the sales force and expanding the deal pipeline.
- Analyst Ratings: Despite TD Cowen and BTIG lowering their price targets to $12 and $15 respectively, both maintained 'Buy' ratings, reflecting analysts' confidence in the company's future performance, particularly with an upcoming product launch and improving margins.
- Financial Health: By the end of 2025, Outset Medical had cash reserves of $173 million, and adjusted net loss decreased from $19.30 million to $15.10 million, indicating progress in cost control and financial stability.
- Future Outlook: Management projected 2026 revenue between $125 million and $130 million, with a non-GAAP gross margin in the low-to-mid-40% range, demonstrating confidence in future growth and responsiveness to market demand.
See More
Outset Medical Reports Q4 2025 Earnings Highlights
- Financial Performance Boost: Outset Medical reported total revenue of $119.5 million for 2025, a 5% increase over 2024, with Q4 revenue at $28.9 million and product revenue at $19.9 million, indicating robust growth in the market.
- Margin Improvement: The non-GAAP gross margin reached 42.9% in Q4, expanding over 500 basis points year-over-year, with product gross margin exceeding 50% for the first time, showcasing significant progress in cost control and pricing strategies.
- High Customer Satisfaction: The Tablo system is now utilized at approximately 1,000 acute care sites in the U.S., with customer satisfaction remaining above 95%, reflecting the company's ongoing commitment to customer service and product quality.
- Optimistic Future Outlook: The company anticipates 2026 revenue between $125 million and $130 million, representing a growth rate of 5% to 9%, while gross margins are expected to remain in the low to mid-40% range, demonstrating confidence in future growth.
See More
Outset Medical Reports Q4 Earnings Miss
- Earnings Report Disappointment: Outset Medical reported a Q4 non-GAAP EPS of -$0.84, missing expectations by $0.16, indicating challenges in profitability that may affect investor confidence.
- Slight Revenue Decline: The company's Q4 revenue was $28.9 million, down 2.0% year-over-year, and while it met market expectations, the ongoing revenue decline may reflect weak market demand, necessitating a review of future sales strategies.
- Market Reaction Analysis: Given the earnings miss, Outset Medical's stock price may face downward pressure, prompting investors to carefully assess its future growth potential and competitive positioning in the market.
- Industry Outlook: In the context of increasing competition in the medical device sector, Outset Medical must implement effective measures to enhance product sales and market share to address future challenges and achieve sustainable growth.
See More
Outset Medical to Announce Q4 Earnings on February 11
- Earnings Announcement Schedule: Outset Medical (OM) is set to release its Q4 2023 earnings on February 11 after market close, with a consensus EPS estimate of -$0.68, reflecting an 83.8% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Expectations Decline: Analysts project quarterly revenue of $28.9 million, down 2.0% year-over-year, suggesting that the company may face competitive pressures that could hinder its future growth potential.
- Historical Performance Review: Over the past two years, OM has beaten EPS estimates 50% of the time and revenue estimates 63% of the time, indicating some capacity to exceed expectations, although recent downward revisions may impact investor confidence.
- Estimates Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and three downward revisions, while revenue estimates have had no upward revisions and one downward revision, reflecting a cautious market outlook on OM's future performance.
See More
Outset Medical (OM) Q1 2026 Earnings Transcript
See More
Halper Sadeh LLC Investigates Outset Medical Executives' Responsibilities
- Shareholder Rights Protection: Halper Sadeh LLC is investigating whether executives of Outset Medical, Inc. breached their fiduciary duties, potentially allowing shareholders to seek corporate governance reforms and fund recovery, thereby enhancing company transparency and accountability.
- Legal Fee Arrangement: The law firm commits to handling the case on a no upfront cost basis, meaning shareholders can pursue their legal rights without incurring additional financial burdens, thus lowering the barriers to participation.
- Importance of Shareholder Involvement: Shareholder participation is viewed as crucial for improving company policies and oversight mechanisms, which can drive the company towards more transparent and effective management, ultimately enhancing overall shareholder value.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide affected by securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for victims, demonstrating its strength in protecting investor rights.
See More
Outset Medical Q4 Results Show Strong Analyst Support
- Performance Overview: Outset Medical reported Q4 revenue of $28.90 million, a 2% year-over-year decline, while total revenue for 2025 rose 5% to $119.50 million, indicating efforts in stabilizing the sales force and expanding the deal pipeline.
- Analyst Ratings: Despite TD Cowen and BTIG lowering their price targets to $12 and $15 respectively, both maintained 'Buy' ratings, reflecting analysts' confidence in the company's future performance, particularly with an upcoming product launch and improving margins.
- Financial Health: By the end of 2025, Outset Medical had cash reserves of $173 million, and adjusted net loss decreased from $19.30 million to $15.10 million, indicating progress in cost control and financial stability.
- Future Outlook: Management projected 2026 revenue between $125 million and $130 million, with a non-GAAP gross margin in the low-to-mid-40% range, demonstrating confidence in future growth and responsiveness to market demand.
See More
Outset Medical Reports Q4 2025 Earnings Highlights
- Financial Performance Boost: Outset Medical reported total revenue of $119.5 million for 2025, a 5% increase over 2024, with Q4 revenue at $28.9 million and product revenue at $19.9 million, indicating robust growth in the market.
- Margin Improvement: The non-GAAP gross margin reached 42.9% in Q4, expanding over 500 basis points year-over-year, with product gross margin exceeding 50% for the first time, showcasing significant progress in cost control and pricing strategies.
- High Customer Satisfaction: The Tablo system is now utilized at approximately 1,000 acute care sites in the U.S., with customer satisfaction remaining above 95%, reflecting the company's ongoing commitment to customer service and product quality.
- Optimistic Future Outlook: The company anticipates 2026 revenue between $125 million and $130 million, representing a growth rate of 5% to 9%, while gross margins are expected to remain in the low to mid-40% range, demonstrating confidence in future growth.
See More
Outset Medical Reports Q4 Earnings Miss
- Earnings Report Disappointment: Outset Medical reported a Q4 non-GAAP EPS of -$0.84, missing expectations by $0.16, indicating challenges in profitability that may affect investor confidence.
- Slight Revenue Decline: The company's Q4 revenue was $28.9 million, down 2.0% year-over-year, and while it met market expectations, the ongoing revenue decline may reflect weak market demand, necessitating a review of future sales strategies.
- Market Reaction Analysis: Given the earnings miss, Outset Medical's stock price may face downward pressure, prompting investors to carefully assess its future growth potential and competitive positioning in the market.
- Industry Outlook: In the context of increasing competition in the medical device sector, Outset Medical must implement effective measures to enhance product sales and market share to address future challenges and achieve sustainable growth.
See More
Outset Medical to Announce Q4 Earnings on February 11
- Earnings Announcement Schedule: Outset Medical (OM) is set to release its Q4 2023 earnings on February 11 after market close, with a consensus EPS estimate of -$0.68, reflecting an 83.8% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Expectations Decline: Analysts project quarterly revenue of $28.9 million, down 2.0% year-over-year, suggesting that the company may face competitive pressures that could hinder its future growth potential.
- Historical Performance Review: Over the past two years, OM has beaten EPS estimates 50% of the time and revenue estimates 63% of the time, indicating some capacity to exceed expectations, although recent downward revisions may impact investor confidence.
- Estimates Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and three downward revisions, while revenue estimates have had no upward revisions and one downward revision, reflecting a cautious market outlook on OM's future performance.
See More
